ARTICLE | Financial News
Fusion raises $105M series B for radiopharmaceutical pipeline
April 2, 2019 6:58 PM UTC
Aiming to advance its pipeline of targeted α-particle radiopharmaceuticals for cancer, Fusion raised $105 million in an oversubscribed series B round led by Varian and new investor OrbiMed Advisors.
Fusion Pharmaceuticals Inc. (Hamilton, Ontario) labels antibodies with the radioisotope actinium-225 using a proprietary linker that it says increases the excretion of unbound radioactive particles, which could improve safety (see "Radio Fusion")...
BCIQ Company Profiles